MARK H KAPLAN, MD
Osteopathic Medicine at Canton Center Rd, Westland, MI
License number
Michigan 4301084949
Category
Osteopathic Medicine
Type
Internal Medicine
License number
Michigan 4301084949
Category
Osteopathic Medicine
Type
Infectious Disease
Address
Address
2
1051 NORTH Canton Center Rd, Westland, MI 48187
3621 Kms Pl, Ann Arbor, MI 48108
3621 Kms Pl, Ann Arbor, MI 48108
Phone
(734) 647-5899
(734) 936-2047
(734) 936-2047
Professional information
See more information about MARK H KAPLAN at trustoria.com
Dr. Mark H Kaplan, Canton MI - MD (Doctor of Medicine)
Dr. Mark H Kaplan, Canton MI - MD (Doctor of Medicine)
Specialties:
Infectious Disease Medicine
Address:
1051 N Canton Center Rd, Canton 48187
(734) 647-5899 (Phone)
(734) 647-5899 (Phone)
Certifications:
Infectious Disease, 1974, Internal Medicine, 1972
Awards:
Healthgrades Honor Roll
Languages:
English, French
Education:
Medical School
Joan Sanford I Weill Medical College Of Cornell University
Graduated: 1966
Bellevue Hospital Cornell Division
Graduated: 1967
Meml Hospital
Graduated: 1971
New York City Bellevue Hospital
Graduated: 1968
New York City Meml Hospital
Graduated: 1974
Joan Sanford I Weill Medical College Of Cornell University
Graduated: 1966
Bellevue Hospital Cornell Division
Graduated: 1967
Meml Hospital
Graduated: 1971
New York City Bellevue Hospital
Graduated: 1968
New York City Meml Hospital
Graduated: 1974
Antiviral Treatment Of Lymphoma And Cancer
Antiviral Treatment Of Lymphoma And Cancer
US Patent:
2012013, May 31, 2012
Filed:
May 21, 2010
Appl. No.:
13/321416
Inventors:
Mark H. Kaplan - Ann Arbor MI, US
David Markovitz - Ann Arbor MI, US
David Markovitz - Ann Arbor MI, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF MICHIGAN - Ann Arbor MI
International Classification:
A61K 31/7072, A61K 31/7076, A61K 31/536, A61K 31/551, A61K 31/505, A61K 31/4418, A61K 31/427, A61K 31/635, A61K 31/496, A61P 35/00, C12Q 1/70, C40B 30/00, A61P 31/12, A61K 31/513, A61K 31/7068, A61K 31/52, A61K 31/708
US Classification:
514 45, 514 50, 514 81, 5142305, 514220, 514272, 514357, 514365, 514158, 51425301, 435 5, 506 7, 514274, 514 49, 5142634
Abstract:
Compositions and methods to treat lymphoma and cancer are disclosed. In particular, the method teaches treatment of lymphoma and cancer using anti-HERV-K(HML-2) therapies. Further taught are compositions and methods for characterizing patient samples to, for example, select or identify therapeutic options or assess the impact of therapies.
Elf3 Gene Compositions And Methods
Elf3 Gene Compositions And Methods
US Patent:
2010031, Dec 16, 2010
Filed:
May 17, 2010
Appl. No.:
12/800539
Inventors:
Mark H. Kaplan - Ann Arbor MI, US
Michael H. Dosik - East Setauket NY, US
Xue-Ping Wang - Port Washington NY, US
Michael H. Dosik - East Setauket NY, US
Xue-Ping Wang - Port Washington NY, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5′ untranslated region, and a novel Alu, Alu. Methods and kits using primers or probes to detect the presence of these ELF3 gene compositions are also provided. Methods for determining whether a cell comprises a virus are also provided.
Elf3 Gene Compositions And Methods
Elf3 Gene Compositions And Methods
US Patent:
7718783, May 18, 2010
Filed:
Nov 21, 2003
Appl. No.:
10/535378
Inventors:
Mark H. Kaplan - Ann Arbor MI, US
Michael H. Dosik - East Setauket NY, US
Xue-Ping Wang - Port Washington NY, US
Michael H. Dosik - East Setauket NY, US
Xue-Ping Wang - Port Washington NY, US
International Classification:
C07H 21/02, C12Q 1/68
US Classification:
536 231, 435 6
Abstract:
ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5′ untranslated region, and a novel Alu, Alu. Methods and kits using primers or probes to detect the presence of these ELF3 gene compositions are also provided. Methods for determining whether a cell comprises a virus are also provided.
Herv Group Ii Viruses In Lymphoma And Cancer
Herv Group Ii Viruses In Lymphoma And Cancer
US Patent:
2008026, Oct 23, 2008
Filed:
Sep 10, 2007
Appl. No.:
11/852369
Inventors:
David Markovitz - Ann Arbor MI, US
Mark H. Kaplan - Ann Arbor MI, US
Michael H. Dosik - Setauket NY, US
Mark H. Kaplan - Ann Arbor MI, US
Michael H. Dosik - Setauket NY, US
Assignee:
The Regents of the University of Michigan - Ann Arbor MI
International Classification:
C12Q 1/68, G01N 33/574, C12Q 1/02
US Classification:
435 6, 435 723, 435 29
Abstract:
The present invention relates to compositions and methods for cancer diagnosis and therapy, including but not limited to, cancer markers. In particular, the present invention relates to HERV-K(HML-2) target titers as diagnostic markers, and HERV-K(HML-2) therapeutic targets for HIV-related cancers, and other cancers.